NCT01381575 - Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls | Biotech Hunter

Enrollment

1,447

Participants

Timeline

Start Date

June 29, 2011

Primary Completion Date

June 28, 2012

Study Completion Date

November 13, 2014

Conditions

Infections, Papillomavirus

Interventions

BIOLOGICAL

GSK Biologicals' HPV vaccine 580299

Subjects received 2 or 3 doses of HPV vaccine administered intramuscularly.

Trial Locations (33)

100

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan District

10330

GSK Investigational Site, Bangkok

12100

GSK Investigational Site, Cuneo

13055

GSK Investigational Site, Berlin

16132

GSK Investigational Site, Genoa

20122

GSK Investigational Site, Milan

22159

GSK Investigational Site, Hamburg

24937

GSK Investigational Site, Flensburg

30625

GSK Investigational Site, Hanover

30657

GSK Investigational Site, Hanover

35128

GSK Investigational Site, Padua

38302

GSK Investigational Site, Wolfenbüttel

38440

GSK Investigational Site, Wolfsburg

47533

GSK Investigational Site, Kleve-Materborn

50200

GSK Investigational Site, Chiang Mai

54290

GSK Investigational Site, Trier

55116

GSK Investigational Site, Mainz

55131

GSK Investigational Site, Mainz

77694

GSK Investigational Site, Kehl

79106

GSK Investigational Site, Freiburg im Breisgau

83471

GSK Investigational Site, Schönau am Königssee

97070

GSK Investigational Site, Würzburg

97100

GSK Investigational Site, Ragusa

99423

GSK Investigational Site, Weimar

V3K 3P4

GSK Investigational Site, Coquitlam

B3K 6R8

GSK Investigational Site, Halifax

P3E 1H5

GSK Investigational Site, Greater Sudbury

M9W 4L6

GSK Investigational Site, Toronto

N4S 5P5

GSK Investigational Site, Woodstock

J1H 2G2

GSK Investigational Site, Sherbrooke

09127

GSK Investigational Site, Cagliari

Unknown

GSK Investigational Site, Taipei